During cancer development, mutation of the TP53 gene not only results in the ablation of wild type p53 tumor-suppressor activity but also gives rise to a mutant protein that encompasses oncogenic functions (Oren et al., 2010; Hou et al., 2013). This evidence concerns the gene TP53 and neoplasm.